Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

A user shared their experience with hair recovery after a second shedding phase while using Finasteride. They advise staying consistent with treatment, as it can take 1-2 years or more to see results, and also mention using Ketoconazole but are unsure of its effectiveness.

Topical melatonin may have positive effects on hair loss by keeping hair in the growing phase. Users are discussing product recommendations and DIY methods for incorporating melatonin into their hair care routine.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.

A 25-year-old experienced significant hair regrowth using 5% minoxidil for 9.5 months despite an initial shed and a second shedding phase lasting 3.5 months. They encourage others to persist with minoxidil treatment through shedding as regrowth can occur.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The user is experiencing hair loss and is considering using finasteride again, along with ketoconazole shampoo and curl cream, to manage their long hair. They are concerned about the appearance of new hair growth and the potential shedding phase from minoxidil.

The user is experiencing hair shedding after one month of using 3mg minoxidil, 1mg finasteride, and Nizoral twice a week. Others reassure that shedding is normal and improvements in hair density and hairline are expected after the shedding phase.

The user experienced hair loss starting at 16 and used finasteride and minoxidil, later switching to dutasteride and oral minoxidil, which improved hair thickness after an initial shedding phase. The user also noted the importance of using shampoo to manage dermatitis and maintain scalp health.

Dutasteride, especially at higher doses, is considered more effective than Minoxidil for hair regrowth by blocking DHT, which causes hair loss. Combining Dutasteride with Minoxidil may enhance hair recovery by prolonging the hair growth phase.

Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hair follicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.

Finasteride can cause scalp itch and inflammation, possibly due to DHT changes, but these effects are often temporary and part of the shedding phase. Consistent use of finasteride may show results after 6 months, with potential hair regrowth and slowed hair loss.

The user experienced increased hair thinning after switching from finasteride and minoxidil to dutasteride, despite some users suggesting it might be a temporary shedding phase. The user is considering using RU58841 but is unsure about its safety.

The user has been using 2mg minoxidil and 1mg finasteride daily for over a year, with inconsistent use for two months, and is experiencing a shedding phase. Suggestions include adding dutasteride, micro-needling, and considering a shorter haircut to manage appearance during shedding.

A user shared their 7-month progress using oral minoxidil (2.5mg) and recently started finasteride (1mg) daily, reporting significant hair improvement without side effects. They noticed thicker beard growth and some hair thickening at the crown, with no shedding phase yet.

The user is considering using Tretinoin every other day alongside daily Minoxidil to manage hair loss and is concerned about inconsistent absorption affecting regrowth. They have noticed a significant reduction in shedding but are unsure if it's due to Tretinoin or the end of the Minoxidil/finasteride shedding phase.